Korsana Biosciences closed a $380 million financing round to support its work in the coming years, including through multiple clinical milestones for its lead program KRSA-028.
Published
Signal category
Capital & Finance
Quote
“We also closed our previously announced $380 million financing, which will support our work in the coming years, including through multiple clinical milestones for our lead program, KRSA-028, a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease.”
— Korsana Biosciences team
Company
Korsana Biosciences
Building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases.
- Industry
- Biotechnology Research
- Location
- Waltham, US
- Company size
- 34 employees
Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company’s lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA™), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases. For more information, please visit www.korsana.com.